The P-Glycoprotein 170: Just a Multidrug Resistance Protein or a Protean Molecule?

ABC Transporters and Multidrug Resistance

Volumn , Issue , 2009, Pages 15-46

  Grandjean Forestier, Fabienne ^a   Stenger, Christophe ^a   Robert, Jacques ^b   Verdier, Mireille ^a   Ratinaud, Marie Hélène ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b INSTITUT BERGONIÉ   (France)

Author keywords

ATP binding cassette (ABC) proteins diversified superfamily in living kingdoms; P glycoprotein 170; Tissular, cellular, and organelle expression of P gp 170

Indexed keywords

EID: 84880180369     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470495131.ch1     Document Type: Chapter

References (173)

1. Kimura Y, Morita SY, Matsuo M, and Ueda K. 2007. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98: 1303-1310.
2. Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127.
3. Dassa E and Bouige P. 2001. The ABC of ABCS: A phylogenetic and functional classification of ABC systems in living organisms. Res Microbiol 152: 211-229.
4. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
5. Higgins CF. 2007. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757.
6. Juliano RL and Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
7. Gottesman MM and Ling V. 2006. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett 580: 998-1009.
8. Loo TW and Clarke DM. 2005. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206: 173-185.
9. Vaalburg W, Hendrikse NH, Elsinga PH, Bart J, and van Waarde A. 2005. P-glycoprotein activity and biological response. Toxicol Appl Pharmacol 207: 257-260.
10. Chinn LW and Kroetz DL. 2007. ABCB1 pharmacogenetics: Progress, pitfalls, and promise. Clin Pharmacol Ther 81: 265-269.
11. Hennessy M and Spiers JP. 2007. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55: 1-15.
12. Callaghan R, Crowley E, Potter S, and Kerr ID. 2008. P-glycoprotein: So many ways to turn it on. J Clin Pharmacol 48: 365-378.
13. Lin T, Islam O, and Heese K. 2006. ABC transporters, neural stem cells and neurogenesis-A different perspective. Cell Res 16: 857-871.
14. Sarkadi B, Homolya L, Szakács G, and Váradi A. 2006. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.
15. Huang Y and Sadée W. 2006. Membrane transporters and channels in chemore-sistance and-sensitivity of tumor cells. Cancer Lett 239: 168-182.
16. Van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P et al. 1996. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517.
17. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, and Roninson IB. 1990. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 265: 506-514.
18. Mickley LA, Spengler BA, Knutsen TA, Biedler JL, and Fojo T. 1997. Gene rearrangement: A novel mechanism for MDR-1 gene activation. J Clin Invest 99: 1947-1957.
19. Huff LM, Lee J-S, Robey RW, and Fojo T. 2006. Characterization of gene rearrangement leading to activation of MDR-1. JBiol Chem 281: 36501-36509.
20. Van Groenigen M, Valentijn LJ, and Baas F. 1993. Identification of a functional initiator sequence in the human MDR1 promoter. Biochim Biophys Acta 1172: 138-146.
21. Huff LM, Wang Z, Iglesias A, Fojo T, and Lee JS. 2005. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Cancer Res 65: 11694-11703.
22. Lutterbach B, Sun D, Schuetz J, and Hiebert SW. 1998. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol 18: 3604-3611.
23. Randle RA, Raguz S, Higgins CF, and Yagüe E. 2007. Role of the highly structured 5'-end region of MDR1 mRNA in P-glycoprotein expression. Biochem J 406: 445-455.
24. Chen G, Jaffrezou JP, Fleming WH, Duran GE, and Sikic BI. 1994. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 54: 4980-4987.
25. Desiderato L, Davey MW, and Piper AA. 1997. Demethylation of the human MDR1 5' region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet 23: 391-400.
26. Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M et al. 1999. Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 262: 924-932.
27. Chaudhary PM and Roninson IB. 1993. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639.
28. Labialle S, Gayet L, Marthinet E, Rigal D, and Baggetto LG. 2002. Transcriptional regulators of the human multidrug resistance 1 gene: Recent views. Biochem Pharmacol 64: 943-948.
29. Ogretmen B and Safa AR. 1999. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry 38: 2189-2199.
30. Rohlff C and Glazer RI. 1998. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol 12: 383-386.
31. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K et al. 1997. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3: 447-450.
32. Ogretmen B and Safa AR. 2000. Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. Biochemistry 39: 194-204.
33. Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M et al. 1998. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273: 5997-6000.
34. Johnson RA, Ince TA, and Scotto KW. 2001. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276: 27716-27720.
35. Zhan M, Yu D, Lang A, Li L, and Pollock RE. 2001. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 92: 1556-1566.
36. Zhan M, Yu D, Liu J, Glazer RI, Hannay J, and Pollock RE. 2005. Transcriptional repression of protein kinase C alpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem 280: 4825-4833.
37. Johnson RA, Shepard EM, and Scotto KW. 2005. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J Biol Chem 280: 13213-13219.
38. Okamura H, Yoshida K, Sasaki E, Morimoto H, and Haneji T. 2004. Transcription factor NF-Y regulates mdr1 expression through binding to inverted CCAAT sequence in drug-resistant human squamous carcinoma cells. Int J Oncol 25: 1031-1037.
39. Chen GK, Sale S, Tan T, Ermoian RP, and Sikic BI. 2004. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol 65: 906-916.
40. Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, and Baggetto LG. 2004. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein. Nucleic Acids Res 32: 3864-3876.
41. Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S et al. 2003. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol 163: 321-331.
42. Baker EK, Johnstone RW, Zalcberg JR, and El-Osta A. 2005. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24: 8061-8075.
43. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S et al. 2006. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 27: 195-203.
44. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al. 2001. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69: 169-174.
45. Pawlik A, Baśkiewicz-Masiuk M, Machaliiíski B, Safranow K, and Gawroiíska-Szklarz B. 2005. Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexametha-sone. J Pharm Pharmacol 57: 1421-1425.
46. Siegsmund M, Brinkmann U, Scháffeler E, Weirich G, Schwab M, Eichelbaum M et al. 2002. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 13: 1847-1854.
47. Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, Takagi K et al. 2003. Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2: 1351-1359.
48. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, and Sych Z. 2003. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13: 259-263.
49. Morita N, Yasumori T, and Nakayama K. 2003. Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65: 1843-1852.
50. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R et al. 2003. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22: 1117-1121.
51. Vaclavikova R, Nordgard SH, Alnaes GI, Hubackova M, Kubala E, Kodet R et al. 2008. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): Effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 18: 263-273.
52. Sam SS, Thomas V, Sivagnanam K, Reddy KS, Surianarayanan G, and Chandrasekaran A. 2007. ABCB1 genetic polymorphism and risk of upper aerodi-gestive tract cancers among smokers, tobacco chewers and alcoholics in an Indian population. Pharmacogenet Genomics 17: 861-866.
53. Woodahl EL, Yang Z, Bui T, Shen DD, and Ho RJ. 2004. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 310: 1199-1207.
54. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A et al. 2004. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-1410.
55. Li D, Zhang GL, Lou YQ, Li Q, Wang X, and Bu XY. 2007. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther 32: 89-95.
56. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI et al. 2007. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8: 29-39.
57. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M et al. 2008. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 18: 307-315.
58. Elens L, Capron A, Kerckhove VV, Lerut J, Mourad M, Lison D et al. 2007. 1199G > A and 2677G > T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenet Genomic 17: 873-883.
59. Green H. 2008. Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics 9: 671-674.
60. Jones PM and George AM. 1998. A new structural model for P-glycoprotein. J Membr Biol 166: 133-147.
61. Dawson RJ and Locher KP. 2006. Structure of a bacterial multidrug ABC transporter. Nature 443: 180-185.
62. Zolnerciks JK, Wooding C, and Linton KJ. 2007. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J 21: 3937-3948.
63. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, and Ford RC. 2003. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278: 8294-8299.
64. Rosenberg MF, Callaghan R, Modok S, Higgins CF, and Ford RC. 2005. Threedimensional structure of P-glycoprotein: The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 280: 2857-2862.
65. Vandevuer S, Van Bambeke F, Tulkens PM, and Prévost M. 2006. Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: Insight into the mechanism of ligand migration and binding sites. Proteins 63: 466-478.
66. Lee JY, Urbatsch IL, Senior AE, and Wilkens S. 2008. Nucleotide-induced structural changes in P. glycoprotein observed by electron microscopy. J Biol Chem 283: 5769-5779.
67. Loo TW, Bartlett MC, and Clarke DM. 2006. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem J 396: 537-545.
68. Loo TW, Bartlett MC, and Clarke DM. 2006. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J 399: 351-359.
69. Storm J, O'Mara ML, Crowley EH, Peall J, Tieleman DP, Kerr ID et al. 2007. Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein. Biochemistry 46: 9899-9910.
70. Staats J, Marquardt D, and Center MS. 1990. Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein. J Biol Chem 265: 4084-4090.
71. Parissenti AM, Gannon BR, Villeneuve DJ, Kirwan-rhude AF, Chadderton A, and Gluck S. 1999. Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells. Int J Cancer 82: 893-900.
72. Gupta KP, Ward NE, Gravitt KR, Bergman PJ, and O'Brian CA. 1996. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem 271: 2102-2111.
73. Ratsaninghe D, Phang JM, and Yeh GC. 1998. Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells. Int J Oncol 13: 79-84.
74. Kannan S. 2006. Therapeutic significance of ectophosphatase inhibitors in reversal of multi-drug resistance. Med Hypotheses 66: 1041-1042.
75. Smith CD and Zilfou JT. 1995. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270: 28145-28152.
76. Castro AF, Horton JK, Vanoye CG, and Altenberg GA. 1999. Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochem Pharmacol 58: 1723-1733.
77. Sachs CW, Chambers TC, and Fine RL. 1999. Differential phosphorylation of sites in the linker region of P-glycoprotein by protein kinase C isozymes alpha, beta I, beta II, gamma, delta, epsilon, eta, and zeta. Biochem Pharmacol 58: 1587-1592.
78. Szabó K, Bakos E, Welker E, Müller M, Goodfellow HR, Higgins CF et al. 1997. Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity. JBiol Chem 272: 23165-23171.
79. Ahmad S, Safa AR, and Glazer RI. 1994. Modulation of P-glycoprotein by protein kinase C alpha in a baculovirus expression system. Biochemistry 33: 10313-10318.
80. Lelong-Rebel IH and Cardarelli CO. 2005. Differential phosphorylation patterns of P-glycoprotein reconstituted into a proteoliposome system: Insight into additional unconventional phosphorylation sites. Anticancer Res 25: 3925-3935.
81. Loo TW, Bartlett MC, and Clarke DM. 2004. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains. J Biol Chem 279: 38395-38401.
82. Loo TW and Clarke DM. 1994. Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. J Biol Chem 269: 28683-28689.
83. Loo TW and Clarke DM. 1995. P-glycoprotein. Associations between domains and between domains and molecular chaperones. J Biol Chem 270: 21839-21844.
84. Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele G, Jr. et al. 1995. Inhibition of N--inked glycosylation of P-glycoprotein by tunicamy-cin results in a reduced multidrug resistance phenotype. Br J Cancer 71: 670-675.
85. Zhang Z, Wu JY, Hait WN, and Yang JM. 2004. Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 66: 395-403.
86. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, and Ambudkar SV. 2000. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol 173: 203-214.
87. Urbatsch IL, Wilke-Mounts S, Gimi K, and Senior AE. 2001. Purification and characterization of N-glycosylation mutant mouse and human P-glycoproteins expressed in Pichia pastoris cells. Arch Biochem Biophys 388: 171-177.
88. Greer DA and Ivey S. 2007. Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. Biochim Biophys Acta 1770: 1275-1282.
89. Krueger KE and Srivastava S. 2006. Posttranslational protein modifications: Current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics 5: 1799-1810.
90. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269.
91. Fromm MF. 2003. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33: 6-9.
92. Thuerauf N and Fromm MF. 2006. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 256: 281-286.
93. Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S et al. 2004. A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: Monoglyceride as an active compound. Biofactors 22: 71-74.
94. Leslie EM, Deeley RG, and Cole SP. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216-237.
95. Fromm MF. 2004. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423-429.
96. Bendayan R, Ronaldson PT, Gingras D, and Bendayan M. 2006. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 54: 1159-1167.
97. Ha SN, Hochman J, and Sheridan RP. 2007. Mini review on molecular modeling of P-glycoprotein (Pgp). Curr Top Med Chem 7: 1525-1529.
98. Borst P and Elferink RO. 2002. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592.
99. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E et al. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174.
100. Lin JH and Yamazaki M. 2003. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35: 417-454.
101. Keshet GI, Goldstein I, Itzhaki O, Cesarkas K, Shenhav L, Yakirevitch A et al. 2008. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 368: 930-936.
102. de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, Van de Locht LT, and de Witte TJ. 2006. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34 + CD38-cells. Leukemia 20: 750-754.
103. Chaudhary PM and Roninson IB. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94.
104. Dean M, Fojo T, and Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
105. Gottesman MM and Pastan I. 1988. The multidrug transporter, a double-edged sword. J Biol Chem 263: 12163-12166.
106. Mitsuhashi J, Tsukahara S, Suzuki R, Oh-hara Y, Nishi S, Hosoyama H et al. 2007. Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer. Hum Gene Ther 18: 895-906.
107. Islam MO, Kanemura Y, Tajria J, Mori H, Kobayashi S, Shofuda T et al. 2005. Characterization of ABC transporter ABCB1 expressed in human neural stem/ progenitor cells. FEBS Lett 579: 3473-3480.
108. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y et al. 2008. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 9: 167-174.
109. Stromskaya TP, Rybalkina EY, Zabotina TN, Shishkin AA, and Stavrovskaya AA. 2005. Influence of RARalpha gene on MDR1 expression and P-glycoprotein function in human leukemic cells. Cancer Cell Int 5: 15.
110. Sulová Z, Macejová D, Seres M, Sedlák J, Brtko J, and Breier A. 2008. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol In Vitro 22: 96-105.
111. Gottesman MM, Fojo T, and Bates SE. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
112. Huang CC, Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX et al. 1992. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262-264.
113. Kramer R, Weber TK, Morse B, Arceci R, Staniunas R, Steele G, Jr. et al. 1993. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 67: 959-968.
114. Petrini M, Di Simone D, Favati A, Mattii L, Valentini P, and Grassi B. 1995. GST-pi and P-170 co-expression in multiple myeloma. Br J Haematol 90: 393-397.
115. Soto-Vega E, Arroyo C, Richaud-Patin Y, García-Carrasco M, Vázquez-Lavista LG, and Llorente L. 2008. P-glycoprotein activity in renal clear cell carcinoma. Urol Oncol in press.
116. Sognier MA, Zhang Y, Eberle RL, Sweet KM, Altenberg GA, and Belli JA. 1994. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100). Biochem Pharmacol 48: 391-401.
117. Belhoussine R, Morjani H, Millot JM, Sharonov S, and Manfait M. 1998. Confocal scanning microspectrofluorometry reveals specific anthracyline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells. J Histochem Cytochem 46: 1369-1376.
118. Larsen AK, Escargueil AE, and Skladanowski A. 2000. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85: 217-229.
119. Bour-Dill C, Gramain MP, Merlin JL, Marchal S, and Guillemin F. 2000. Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry 39: 16-25.
120. Benderra Z, Trussardi A, Morjani H, Villa AM, Doglia SM, and Manfait M. 2000. Regulation of cellular glutathione modulates nuclear accumulation of daunoru-bicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer 36: 428-434.
121. Seidel A, Hasmann M, Loser R, Bunge A, Schaefer B, Herzig I et al. 1995. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells. Virchows Arch 426: 249-256.
122. Schindler M, Grabski S, Hoff E, and Simon SM. 1996. Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry 35: 2811-2817.
123. Warren L, Jardillier JC, and Ordentlich P. 1991. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells. Cancer Res 51: 1996-2001.
124. Shapiro AB, Fox K, Lee P, Yang YD, and Ling V. 1998. Functional intracellular P-glycoprotein. Int J Cancer 76: 857-864.
125. Ferrao P, Sincock P, Cole S, and Ashman L. 2001. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukemia. Leuk Res 25: 395-405.
126. Maraldi NM, Zini N, Santi S, Scotlandi K, Serra M, and Baldini N. 1999. P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biol Cell 91: 17-28.
127. Molinari A, Cianfriglia M, Meschini S, Calcabrini A, and Arancia G. 1994. P-glycoprotein expression in the Golgi apparatus of multidrug resistant cells. Int J Cancer 59: 789-795.
128. Fu D, Bebawy M, Kable EPW, and Roufogalis BD. 2004. Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. Int J Cancer 109: 174-181.
129. Bennis S, Ichas F, and Robert J. 1995. Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer 62: 283-290.
130. Rajagopal A and Simon SM. 2003. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 14: 3389-3399.
131. Gong Y, Wang Y, Chen F, Han J, Miao J et al. 2000. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leuk Res 24: 769-774.
132. Munteanu E, Verdier M, Grandjean-Forestier F, Stenger C, Jayat-Vignoles C, Huet S et al. 2006. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol 71: 1162-1174.
133. Solazzo M, Fantappiè O, Lasagna N, Sassoli C, Nosi D, and Mazzanti R. 2006. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res 312: 4070-4078.
134. Paterson JK and Gottesman MM. 2007. P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res 313: 3100-3105.
135. Sakaeda T, Nakamura T, and Okumura K. 2002. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 25: 1391-1400.
136. Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W, and de Vries EG. 1999. Visualization of multidrug resistance in vivo. Eur J Nucl Med 26: 283-293.
137. Sharom FJ. 2006. Shedding light on drug transport: Structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 84: 979-992.
138. Sauna ZE and Ambudkar SV. 2007. About a switch: How P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 6: 13-23.
139. Callaghan R, Berridge G, Ferry DR, and Higgins CF. 1997. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim Biophys Acta 1328: 109-124.
140. Ambudkar SV, Kim IW, and Sauna ZE. 2006. The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27: 392-400.
141. Ambudkar SV, Cardarelli CO, Pashinsky I, and Stein WD. 1997. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem 272: 21160-21166.
142. Shapiro AB and Ling V. 1998. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Eur J Biochem 254: 189-193.
143. Tombline G, Muharemagic A, White LB, and Senior AE. 2005. Involvement of the "occluded nucleotide conformation" of P-glycoprotein in the catalytic pathway. Biochemistry 44: 12879-12886.
144. Stein WD, Cardarelli C, Pastan I, and Gottesman MM. 1994. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45: 763-772.
145. Romsicki Y and Sharom FJ. 1999. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38: 6887-6896.
146. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, and Ford RC. 2003. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278: 8294-8299.
147. Hennessy M and Spiers JP. 2007. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55: 1-15.
148. Shapiro AB and Ling V. 1998. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur J Biochem 254: 181-188.
149. Higgins CF and Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18-21.
150. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L et al. 1993. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462.
151. Romsicki Y and Sharom FJ. 2001. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 40: 6937-6947.
152. Siarheyeva A, Lopez JJ, and Glaubitz C. 2006. Localization of multidrug transporter substrates within model membranes. Biochemistry 45: 6203-6211.
153. Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, and Croop J. 1997. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36: 5685-5694.
154. Raggers RJ, Pomorski T, Holthuis JCM, Kälin N, and Van Meer G. 2000. Lipid traffic: The ABC of transbilayer movement. Traffic 1: 226-234.
155. Van Meer G. 2005. Cellular lipidomics. EMBO J 24: 3159-3165.
156. Borst P, Zelcer N, and Van Helvoort A. 2000. ABC transporters in lipid transport. Biochem Biophys Acta 1486: 128-144.
157. Luker GD, Nilsson KR, Covey DF, and Piwnica-Worms D. 1999. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J Biol Chem 274: 6979-6991.
158. Garrigues A, Escargueil AE, and Orlowski S. 2002. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 99: 10347-10352.
159. Bucher K, Besse CA, Kamau SW, Wunderli-Allenspach H, and Krämer SD. 2005. Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities. Pharm Res 22: 449-457.
160. Basco Z, Nagy H, Goda K, Bene L, Fenyvesi F, Matkó J et al. 2004. Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A 61: 105-116.
161. Reungpatthanaphong P, Marbeuf-Gueye C, Le Moyec L, Salerno M, and Garnier-Suillerot A. 2004. Decrease of P-glycoprotein activity in K562/Adr cells by MbCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts. J Bioenerg Biomembr 36: 533-543.
162. Modok S, Heyward C, and Callaghan R. 2004. P-glycoprotein retains function when reconstituted into a sphingolipid-and cholesterol-rich environment. J Lipid Res 45: 1910-1918.
163. Radeva G, Perabo J, and Sharom FJ. 2005. P-Glycoprotein is localized in interme-diate-density membrane microdomains distinct from classical lipid rafts and cave-olar domains. FEBS J 272: 4924-4937.
164. Johnstone RW, Ruefli AA, and Smyth MJ. 2000. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25: 1-6.
165. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, and Roepe PD. 1997. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36: 11169-11178.
166. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, and Johnstone RW. 2002. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9: 1266-1272.
167. Turzanski J, Grundy M, Shang S, Russell N, and Pallis M. 2005. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol 33: 62-72.
168. Li X, Hong L, Zhao Y, Jin H, Fan R, Du R, Xia L, Luo G, and Fan D. 2007. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax. Biochem Cell Biol 85: 741-750.
169. Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L, and Mazzanti R. 2007. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 67: 4915-4923.
170. Han Z, Hong L, Han Y, Wu K, Han S, Shen H et al. 2007. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J Exp Clin Cancer Res 26: 261-268.
171. Köck K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA et al. 2007. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: Relevance for physiology and pharmacotherapy. Clin Pharmacokine 46: 449-470.
172. Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM et al. 1998. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci USA 95: 6924-6929.
173. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, and Llorente L. 2004. P-glycoprotein in autoimmune diseases. Autoimmun Rev 3: 188-119.